Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress
Rhea-AI Summary
Shattuck Labs (NASDAQ: STTK) has announced an upcoming poster presentation at the 2025 Crohn's and Colitis Congress in San Francisco, California, scheduled for February 6-8, 2025. The presentation will focus on SL-325, a DR3-targeted, antagonistic antibody developed for the treatment of IBD.
The poster will be presented by Dr. Suresh de Silva, Shattuck's Co-Chief Scientific Officer, on Friday, February 7, 2025, from 5:00 PM to 6:30 PM PST at the Congress Exhibit Hall in The Moscone Center. The presentation materials will be made available on the company's website in the Events and Presentations section after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, STTK declined 4.28%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming poster presentation at the 2025 Crohn’s and Colitis Congress being held in San Francisco, California from February 6–8, 2025.
Presentation Details
Format: Poster presentation
Title: Development and Characterization of SL-325, a DR3-Targeted, Antagonistic Antibody for the Treatment of IBD
Presenter: Suresh de Silva, Ph.D., Shattuck’s Co-Chief Scientific Officer
Date/Time: Friday, February 7, 2025; 5:00 PM – 6:30 PM PST
Location: Congress Exhibit Hall, The Moscone Center, Level 1; San Francisco, CA
The poster will be available on the Events and Presentations section of the Company’s website following the presentation.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treatments for autoimmune/inflammatory diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory autoimmune diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor agonist and antagonist therapeutics come together in its lead program, SL-325, a first-in-class DR3 antagonist antibody designed to achieve complete and durable blockade of the clinically validated TL1A/DR3 pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
FAQ
What will Shattuck Labs (STTK) present at the 2025 Crohn's and Colitis Congress?
When and where is Shattuck Labs (STTK) presenting at the 2025 Crohn's and Colitis Congress?
Who will present Shattuck Labs' (STTK) research at the 2025 Crohn's and Colitis Congress?
Where can investors find Shattuck Labs' (STTK) 2025 Crohn's and Colitis Congress presentation materials?
